Skip to main content
SpringerLink
Log in

Treatment of lysosomal storage disorders: successes and challenges

  • ICIEM Symposium 2013
  • Published:
Journal of Inherited Metabolic Disease

Abstract

Treatment options for a number of lysosomal storage disorders have rapidly expanded and currently include enzyme replacement therapy, substrate reduction, chaperone treatment, hematopoietic stem cell transplantation, and gene-therapy. Combination treatments are also explored. Most therapies are not curative but change the phenotypic expression of the disease. The effectiveness of treatment varies considerably between the different diseases, but also between sub-groups of patients with a specific lysosomal storage disorder. The heterogeneity of the patient populations complicates the prediction of benefits of therapy, specifically in patients with milder disease manifestations. In addition, there is a lack of data on the natural history of diseases and disease phenotypes. Initial trial data show benefits on relevant short-term endpoints, but the real world situation may reveal different outcomes. Collaborative international studies are much needed to study the long-term clinical efficacy of treatments, and to detect new complications or associated conditions of the diseases. This review summarizes the available treatment modalities for lysosomal storage disorders and the challenges associated with long term clinical care for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aerts JM, Boot RG, van Eijk M et al (2011) Glycosphingolipids and insulin resistance. Adv Exp Med Biol 721:99–119

    Article  CAS  PubMed  Google Scholar 

  • Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105:2812–2817

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Aldenhoven M, Boelens JJ, de Koning TJ (2008) The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 14:485–498

    Article  CAS  PubMed  Google Scholar 

  • Aldenhoven M, Sakkers RJ, Boelens J, de Koning TJ, Wulffraat NM (2009) Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis 68:1659–1665

    Article  CAS  PubMed  Google Scholar 

  • Arends M, van Dussen L, Biegstraaten M, Hollak CE (2013) Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 161:832–842

    Article  CAS  PubMed  Google Scholar 

  • Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86

    Article  PubMed  Google Scholar 

  • Banugaria SG, Prater SN, Ng YK et al (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13:729–736

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Banugaria SG, Prater SN, Patel TT et al (2013) Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One 8:e67052

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Biffi A, Montini E, Lorioli L et al (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:1233158

    Article  PubMed  Google Scholar 

  • Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C (2010) Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 57:123–145

    Article  PubMed  Google Scholar 

  • Boelens JJ, Rocha V, Aldenhoven M et al (2009) Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant 15:618–625

    Article  PubMed  Google Scholar 

  • Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE (2010) Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol Dis 44:181–187

    Article  CAS  PubMed  Google Scholar 

  • Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359–369

    Article  CAS  PubMed  Google Scholar 

  • Boyd RE, Lee G, Rybczynski P, Benjamin ER, Khanna R, Wustman BA, Valenzano KJ (2013) Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56:2705–2725

    Article  CAS  PubMed  Google Scholar 

  • Capablo JL, Franco R, de Cabezon AS, Alfonso P, Pocovi M, Giraldo P (2007) Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. Epilepsia 48:1406–1408

    Article  CAS  PubMed  Google Scholar 

  • Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ (2006) Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J 273:4082–4092

    Article  CAS  PubMed  Google Scholar 

  • Cox T, Lachmann R, Hollak C et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481–1485

    Article  CAS  PubMed  Google Scholar 

  • Cox-Brinkman J, Boelens JJ, Wraith JE et al (2006) Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 38:17–21

    Article  CAS  PubMed  Google Scholar 

  • Cox-Brinkman J, van den Bergh Weerman MA, Wijburg FA, Aerts JM, Florquin S, van der Lee JH, Hollak CE (2010) Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: effects of enzyme replacement therapy and hematopoietic cell transplantation. Ultrastruct Pathol 34:126–132

    Article  PubMed  Google Scholar 

  • Davidson CD, Ali NF, Micsenyi MC et al (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4:e6951

    Article  PubMed Central  PubMed  Google Scholar 

  • de Fost M, van Noesel CJ, Aerts JM, Maas M, Poll RG, Hollak CE (2008) Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93:1119–1120

    Article  PubMed  Google Scholar 

  • de Ru MH, Boelens JJ, Das AM et al (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6:55

    Article  PubMed Central  PubMed  Google Scholar 

  • de Ruijter J, Valstar MJ, Narajczyk M et al (2012) Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 71:110–120

    Article  PubMed  Google Scholar 

  • Ebbink BJ, Aarsen FK, van Gelder CM et al (2012) Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 78:1512–1518

    Article  CAS  PubMed  Google Scholar 

  • Eisengart JB, Rudser KD, Tolar J et al (2013) Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 162:375–80.e1

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Elleder M (2006) Glucosylceramide transfer from lysosomes–the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis 29:707–715

    Article  CAS  PubMed  Google Scholar 

  • Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16

    Article  CAS  PubMed  Google Scholar 

  • Escolar ML, Poe MD, Provenzale JM et al (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. N Engl J Med 352:2069–2081

    Article  CAS  PubMed  Google Scholar 

  • Fan JQ, Ishii S (2007) Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 274:4962–4971

    Article  CAS  PubMed  Google Scholar 

  • Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1:112–5

    Article  Google Scholar 

  • Favejee MM, Huisstede BM, Bussmann JB, Kruijshaar ME, van der Ploeg AT (2012) Physiotherapy management in late-onset Pompe disease: clinical practice in 88 patients. Mol Genet Metab 107:111–115

    Article  CAS  PubMed  Google Scholar 

  • Field RE, Buchanan JA, Copplemans MG, Aichroth PM (1994) Bone-marrow transplantation in Hurler’s syndrome. Effect on skeletal development. J Bone Joint Surg (Br) 76:975–981

    CAS  Google Scholar 

  • Frustaci A, Chimenti C, Ricci R et al (2001) Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 345:25–32

    Article  CAS  PubMed  Google Scholar 

  • Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30

    Article  PubMed Central  PubMed  Google Scholar 

  • Hacein-Bey-Abina S, Garrigue A, Wang GP et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118:3132–3142

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Helquist P, Maxfield FR, Wiech NL, Wiest O (2013) Treatment of Niemann–pick type C disease by histone deacetylase inhibitors. Neurotherapeutics 10:688–697

    Article  CAS  PubMed  Google Scholar 

  • Heron B, Valayannopoulos V, Baruteau J et al (2012) Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare Dis 7:36

    Article  PubMed Central  PubMed  Google Scholar 

  • Hollak CE, Aerts JM, Ayme S, Manuel J (2011) Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 6:16

    Article  PubMed Central  PubMed  Google Scholar 

  • Hsu J, Northrup L, Bhowmick T, Muro S (2012) Enhanced delivery of alpha-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine 8:731–739

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hughes DA, Pastores GM (2013) Haematological manifestations and complications of Gaucher disease. Curr Opin Hematol 20:41–47

    Article  CAS  PubMed  Google Scholar 

  • Hulkova H, Ledvinova J, Poupetova H, Kohout A, Malinova V, Elleder M (2009) Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process. J Inherit Metab Dis 32:551–559

    Article  CAS  PubMed  Google Scholar 

  • Ito S, Barrett AJ (2013) Gauchers disease–a reappraisal of hematopoietic stem cell transplantation. Pediatr Hematol Oncol 30:61–70

    Article  CAS  PubMed  Google Scholar 

  • Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26

    Article  PubMed Central  PubMed  Google Scholar 

  • Khanna R, Soska R, Lun Y et al (2010) The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther 18:23–33

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kingma SD, Langereis EJ, De Klerk CM et al (2013) An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life. Orphanet J Rare Dis 8:99

    Article  PubMed Central  PubMed  Google Scholar 

  • Kirkegaard T, Roth AG, Petersen NH et al (2010) Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 463:549–553

    Article  CAS  PubMed  Google Scholar 

  • Kuter DJ, Mehta A, Hollak CE et al (2013) Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis 51:116–124

    Article  CAS  PubMed  Google Scholar 

  • Langereis EJ, Borgo A, Crushell E et al (2013) Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis 8:155

    Article  PubMed Central  PubMed  Google Scholar 

  • Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G (2013) Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement. Am J Clin Pathol 140:91–96

    Article  PubMed  Google Scholar 

  • Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A (2012) Autophagy in lysosomal storage disorders. Autophagy 8:719–730

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse. Proc Natl Acad Sci U S A 106:2377–2382

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Machaczka M (2013) Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease. Pediatr Hematol Oncol 30:459–461

    Article  PubMed  Google Scholar 

  • Masciullo M, Santoro M, Modoni A, Ricci E, Guitton J, Tonali P, Silvestri G (2010) Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis 33(Suppl 3):S355–S361

    Article  PubMed  Google Scholar 

  • Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254

    Article  CAS  PubMed  Google Scholar 

  • Muenzer J, Beck M, Eng CM et al (2009a) Multidisciplinary management of Hunter syndrome. Pediatrics 124:e1228–e1239

    Article  PubMed  Google Scholar 

  • Muenzer J, Wraith JE, Clarke LA (2009b) Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123:19–29

    Article  PubMed  Google Scholar 

  • Nietupski JB, Pacheco JJ, Chuang WL et al (2012) Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol Genet Metab 105:621–628

    Article  CAS  PubMed  Google Scholar 

  • Ohashi T (2012) Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev 10(Suppl 1):26–34

    PubMed  Google Scholar 

  • Ortolano S, Vieitez I, Navarro C, Spuch C (2014) Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocrinol Metab Immune Drug Discov 8:9–25

    Article  CAS  Google Scholar 

  • Pan C, Nelson MS, Reyes M et al (2005) Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells. Blood 106:1956–1964

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106:330–344

    Article  CAS  PubMed  Google Scholar 

  • Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6:765–772

    Article  CAS  PubMed  Google Scholar 

  • Pavlova EV, Wang SZ, Archer J, Dekker N, Aerts JM, Karlsson S, Cox TM (2013) B cell lymphoma and myeloma in murine Gaucher’s disease. J Pathol 231:88–97

    Article  CAS  PubMed  Google Scholar 

  • Pineda M, Wraith JE, Mengel E et al (2009) Miglustat in patients with Niemann-Pick disease type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab 98:243–249

    Article  CAS  PubMed  Google Scholar 

  • Pipalia NH, Cosner CC, Huang A et al (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A 108:5620–5625

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Porto C, Cardone M, Fontana F et al (2009) The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 17:964–971

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Porto C, Pisani A, Rosa M et al (2012) Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis 35:513–520

    Article  CAS  PubMed  Google Scholar 

  • Prasad VK, Mendizabal A, Parikh SH et al (2008) Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 112:2979–2989

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Prater SN, Banugaria SG, DeArmey SM et al (2012) (2012) The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14:800–810

    Article  PubMed Central  PubMed  Google Scholar 

  • Rombach SM, Aerts JM, Poorthuis BJ et al (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 7:e47805

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 99:99–108

    Article  CAS  PubMed  Google Scholar 

  • Sanderson S, Green A, Preece MA, Burton H (2006) The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child 91:896–899

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65–77

    Article  CAS  PubMed  Google Scholar 

  • Schiffmann R, Fitzgibbon EJ, Harris C et al (2008) Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 64:514–522

    Article  PubMed Central  PubMed  Google Scholar 

  • Schneider I, Hanisch F, Müller T, Schmidt B, Zierz S (2013) Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months. Wien Med Wochenschr 163:40–44

    Article  PubMed  Google Scholar 

  • Schuchman EH, Ge Y, Lai A et al (2013) Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 8:e54459

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Scott CR, Elliott S, Buroker N et al (2013) Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr 163:498–503

    Article  CAS  PubMed  Google Scholar 

  • Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH (2009) Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med 11:425–433

    Article  CAS  PubMed  Google Scholar 

  • Shayman JA (2010) ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35:613–620

    CAS  PubMed Central  PubMed  Google Scholar 

  • Simonaro CM, D’Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, Schuchman EH (2008) Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 172:112–122

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Solanki GA, Martin KW, Theroux MC et al (2013) Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management. J Inherit Metab Dis 36:339–355

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tajima Y, Kawashima I, Tsukimura T et al (2009) Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am J Hum Genet 85:569–580

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137–148

    Article  CAS  PubMed  Google Scholar 

  • Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397–398

    Article  PubMed  Google Scholar 

  • van der Beek NA, de Vries JM, Hagemans ML (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88

    Article  PubMed Central  PubMed  Google Scholar 

  • van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406

    Article  PubMed  Google Scholar 

  • van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9

    Article  PubMed  Google Scholar 

  • Vanier MT (2013) Niemann-Pick diseases. Handb Clin Neurol 113:1717–1721

    Article  PubMed  Google Scholar 

  • Vellodi A, Tylki-Szymanska A, Davies EH et al (2009) Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 32:660–664

    Article  CAS  PubMed  Google Scholar 

  • Visigalli I, Delai S, Politi LS et al (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116:5130–5139

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Walker R, Belani KG, Braunlin EA et al (2013) Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 36:211–219

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Weidemann F, Niemann M, Stork S et al (2013a) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331–341

    Article  CAS  PubMed  Google Scholar 

  • Weidemann F, Sanchez-Nino MD, Politei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A (2013b) Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 8:116

    Article  PubMed Central  PubMed  Google Scholar 

  • Weinreb NJ, Lee RE (2013) Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy. Crit Rev Oncog 18:177–195

    Article  PubMed  Google Scholar 

  • Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S (2004) Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 24:97–101

    Article  PubMed  Google Scholar 

  • Wraith JE (2013) Mucopolysaccharidoses and mucolipidoses. Handb Clin Neurol 113:1723–1729

    Article  PubMed  Google Scholar 

  • Wraith JE, Beck M, Lane R et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 120:e37–e46

    Article  PubMed  Google Scholar 

  • Yang C, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, Zhuang Z (2013) Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci U S A 110:966–971

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Young-Gqamana B, Brignol N, Chang HH et al (2013) Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One 8:e57631

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zimran A (2011) How I treat Gaucher disease. Blood 118:1463–1471

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Endocrinology and Metabolism, SPHINX, Amsterdam Lysosome Center, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Carla E. M. Hollak & Frits A. Wijburg

  2. Department of Pediatric Metabolic Disorders, Academic Medical Center, Amsterdam, The Netherlands

    Frits A. Wijburg

Authors
  1. Carla E. M. Hollak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frits A. Wijburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla E. M. Hollak.

Additional information

Communicated by: Michael J. Bennett

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hollak, C.E.M., Wijburg, F.A. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis 37, 587–598 (2014). https://doi.org/10.1007/s10545-014-9718-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-014-9718-3

Keywords

Search

Navigation